Practical Multidisciplinary Strategies for Adverse Event Management in HR+/HER2-Negative Advanced Breast Cancer

In this closing segment, Dr. Neil Iyengar invites the panel to synthesize key takeaways from the discussion by reflecting on practical, clinic-level strategies for managing common adverse events associated with PI3K and AKT pathway inhibitors in HR+/HER2-negative advanced breast cancer. The panel highlights overarching principles that span diarrhea, hyperglycemia, and dermatologic toxicities, emphasizing early patient education, proactive monitoring, and timely multidisciplinary intervention. Panelists discuss how coordinated workflows among physicians, advanced practice providers, pharmacists, and support staff enable early identification of toxicity trends and help prevent unnecessary treatment interruptions. The conversation reinforces the importance of setting patient expectations, encouraging prompt symptom reporting, and individualizing management strategies based on patient risk factors. The segment concludes with closing remarks that underscore the value of applying guideline-informed, evidence-based approaches to support treatment adherence, optimize patient experience, and improve outcomes in routine clinical practice.